SP1 Impact of a paediatric cystic fibrosis (CF) pharmacist within a CF multidisciplinary clinic

Aim In 2019 new cystic fibrosis transmembrane conductance regulator (CFTR) modulators were commissioned by NHS England for a large proportion of people with Cystic Fibrosis (CF) and the paediatric pharmacy team adopted mechanisms to support their initiation integrating into CF multidisciplinary (MDT) clinic. Although driver change at time was this roll-out, NHSE specialised commissioning service specification 1 several national standards 2,3 , state that all children should see specialist pharmacist annual review have direct access them other appointments. We aimed assess impact embedded within Method Mixed methods study utilising quantitative data evaluate pharmacists’ medicines optimisation (MO) activities, qualitative using structured questionnaires seek views MDT working clinic, family’s attending clinic in August 2021. MO activities (e.g., dose optimisation, reconciliation, prescribing, managing supply, counselling) recorded seen during outpatient clinics between June 2020 The project registered trusts clinical audit department. Results pharmacists actively involved 535 patient episodes carried out 1477 mean 2.76 per episode (median 3; range 1–14). 50% (746) related discrepancies letters identified through reconciliation; 18.5% (273) answering queries; 10% (146) hospital supply; 5% (73) on communication transfer care; 4% (60) formulation changes; 3.5% (52) optimisation; 2% (30) monitoring advice CFTR modulators; 0.6% (7) commencing medication; 0.5% (9) deprescribing 0.3% (4) alternative drug. 182 prescriptions written period, including updating homecare following any changes made Questionnaires revealed (n=18) patients/families (n=21) viewed presence as extremely positive. Comments included: ‘Pharmacist always be present it improves experience flow’; ‘It’s great having however extra bodies takes rest longer patient’; ‘Really useful able speak each time, especially these early days when are changed/new introduced.’ Conclusion A has improved CF. Despite initial concerns raised pressures MDT, children, parent/carers positively. With availability increasing complexity pharmaceutical care, significant interactions requirements, need provide outpatients, well inpatients, never been greater. References England. National Service Specification (Children). 2018/19. [Online]. Available from: https://www.england.nhs.uk/wp-content/uploads/2018/07/a01Sb-spec-cystic-fibrosis-child.pdf Trust. Standards Clinical Care Children Adults UK. 2011. https://www.cysticfibrosis.org.uk/sites/default/files/2020-12/Cystic%20Fibrosis%20Trust%20Standards%20of%20care.pdf Institute Health Excellence. Fibrosis: diagnosis management. 2017. https://www.nice.org.uk/guidance/ng78